Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 3/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 5/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.38 |
| ▸ | TLR4 | O00206 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.35 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19050673 | 0.99 | MRGPRX1 (0.40) | MRGPRX1HRH1BRAFBRD4TLR4 | |
| SCHEMBL391647 | 0.95 | MRGPRX1 (0.44) | MRGPRX1HRH1BRAFTLR4MEN1 | |
| SCHEMBL19049852 | 0.90 | MRGPRX1 (0.39) | MRGPRX1HRH1BRAFBRD4TLR4 | |
| SCHEMBL19050657 | 0.87 | MEN1 (0.47) | MRGPRX1HRH1BRAFBRD4TLR4 | |
| SCHEMBL387833 | 0.86 | MAP2K1 (0.51) | BRAFMAP2K2MAP2K1 | |
| SCHEMBL392673 | 0.85 | MAP2K1 (0.50) | BRAFMAP2K2MAP2K1 | |
| SCHEMBL14263851 | 0.83 | MAP2K2 (0.40) | MEN1MAPK1KMT2AMAP2K2MAP2K1 | |
| SCHEMBL19050690 | 0.83 | MRGPRX1 (0.41) | MRGPRX1HRH1BRAFTLR4MEN1 | |
| SCHEMBL387927 | 0.83 | MAP2K1 (0.44) | MRGPRX1BRAFTLR4KMT2AMAP2K2 | |
| SCHEMBL391574 | 0.81 | MAP2K1 (0.53) | BRAFMAP2K2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MRGPRX1 1641/4885HRH1 1890/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.